X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Glenmark Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs MYLAN (US) - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GLENMARK PHARMA   MYLAN
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-17
MYLAN
Dec-14
GLENMARK PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs9934,183-   
Low Rs7292,948-   
Sales per share (Unadj.) Rs325.51,431.9-  
Earnings per share (Unadj.) Rs39.3172.5-  
Cash flow per share (Unadj.) Rs48.7277.7-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs159.2711.8-  
Shares outstanding (eoy) m282.17378.37-   
Bonus/Rights/Conversions ESOPOI-  
Price / Sales ratio x2.62.5 106.2%   
Avg P/E ratio x21.920.7 106.0%  
P/CF ratio (eoy) x17.712.8 137.8%  
Price / Book Value ratio x5.45.0 108.0%  
Dividend payout %5.10-   
Avg Mkt Cap Rs m242,9911,348,943 18.0%   
No. of employees `00013.025.0 51.9%   
Total wages/salary Rs m16,4080-   
Avg. sales/employee Rs Th7,083.921,671.6 32.7%   
Avg. wages/employee Rs Th1,265.40-   
Avg. net profit/employee Rs Th855.12,610.7 32.8%   
INCOME DATA
Net Sales Rs m91,857541,790 17.0%  
Other income Rs m374-3,158 -11.8%   
Total revenues Rs m92,230538,632 17.1%   
Gross profit Rs m20,367134,746 15.1%  
Depreciation Rs m2,64439,792 6.6%   
Interest Rs m2,37323,370 10.2%   
Profit before tax Rs m15,72468,426 23.0%   
Minority Interest Rs m0-281 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8100-   
Tax Rs m3,8272,877 133.0%   
Profit after tax Rs m11,08865,267 17.0%  
Gross profit margin %22.224.9 89.2%  
Effective tax rate %24.34.2 578.8%   
Net profit margin %12.112.0 100.2%  
BALANCE SHEET DATA
Current assets Rs m68,746476,305 14.4%   
Current liabilities Rs m27,027372,375 7.3%   
Net working cap to sales %45.419.2 236.8%  
Current ratio x2.51.3 198.9%  
Inventory Days Days8578 108.9%  
Debtors Days Days96107 89.1%  
Net fixed assets Rs m24,132125,341 19.3%   
Share capital Rs m28219,159 1.5%   
"Free" reserves Rs m44,6430-   
Net worth Rs m44,925269,323 16.7%   
Long term debt Rs m45,363402,342 11.3%   
Total assets Rs m117,6391,084,807 10.8%  
Interest coverage x7.63.9 194.1%   
Debt to equity ratio x1.01.5 67.6%  
Sales to assets ratio x0.80.5 156.3%   
Return on assets %11.48.2 140.0%  
Return on equity %24.724.2 101.8%  
Return on capital %19.113.6 140.5%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m48,0680-   
CASH FLOW
From Operations Rs m6,57471,219 9.2%  
From Investments Rs m-7,124-56,165 12.7%  
From Financial Activity Rs m5,432-18,766 -28.9%  
Net Cashflow Rs m1,992-3,713 -53.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 70.18 Rs / USD

Compare GLENMARK PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare GLENMARK PHARMA With: PANACEA BIOTECH  J.B.CHEMICALS  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  DISHMAN PHARMA  



Today's Market

Of Mutual Funds Off Loading Small Caps, Depreciating Rupee and Key Stocks in Action Today(Pre-Open)

There is an interesting dichotomy in the Indian markets these days. On one hand the BSE Sensex is touching life time highs.

Related Views On News

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6% (Quarterly Result Update)

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Aug 17, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - ALEMBIC PHARMA COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS